Wajant H - Search Results

1

The TWEAK-Fn14 system as a potential drug target.

Wajant H. Wajant H. Br J Pharmacol. 2013 Oct;170(4):748-64. doi: 10.1111/bph.12337. Br J Pharmacol. 2013. PMID: 23957828 Free PMC article. Review.

2

Tumor necrosis factor receptor-associated factor-1 enhances proinflammatory TNF receptor-2 signaling and modifies TNFR1-TNFR2 cooperation.

Wicovsky A, Henkler F, Salzmann S, Scheurich P, Kneitz C, Wajant H. Wicovsky A, et al. Among authors: wajant h. Oncogene. 2009 Apr 16;28(15):1769-81. doi: 10.1038/onc.2009.29. Epub 2009 Mar 16. Oncogene. 2009. PMID: 19287455

3

TNF-like weak inducer of apoptosis inhibits proinflammatory TNF receptor-1 signaling.

Wicovsky A, Salzmann S, Roos C, Ehrenschwender M, Rosenthal T, Siegmund D, Henkler F, Gohlke F, Kneitz C, Wajant H. Wicovsky A, et al. Among authors: wajant h. Cell Death Differ. 2009 Nov;16(11):1445-59. doi: 10.1038/cdd.2009.80. Epub 2009 Jun 26. Cell Death Differ. 2009. PMID: 19557010

4

Superior serum half life of albumin tagged TNF ligands.

Müller N, Schneider B, Pfizenmaier K, Wajant H. Müller N, et al. Among authors: wajant h. Biochem Biophys Res Commun. 2010 Jun 11;396(4):793-9. doi: 10.1016/j.bbrc.2010.04.134. Epub 2010 May 4. Biochem Biophys Res Commun. 2010. PMID: 20447380

5

Soluble and transmembrane TNF-like weak inducer of apoptosis differentially activate the classical and noncanonical NF-kappa B pathway.

Roos C, Wicovsky A, Müller N, Salzmann S, Rosenthal T, Kalthoff H, Trauzold A, Seher A, Henkler F, Kneitz C, Wajant H. Roos C, et al. Among authors: wajant h. J Immunol. 2010 Aug 1;185(3):1593-605. doi: 10.4049/jimmunol.0903555. Epub 2010 Jul 7. J Immunol. 2010. PMID: 20610643

6

Studies of binding of tumor necrosis factor (TNF)-like weak inducer of apoptosis (TWEAK) to fibroblast growth factor inducible 14 (Fn14).

Fick A, Lang I, Schäfer V, Seher A, Trebing J, Weisenberger D, Wajant H. Fick A, et al. Among authors: wajant h. J Biol Chem. 2012 Jan 2;287(1):484-495. doi: 10.1074/jbc.M111.287656. Epub 2011 Nov 11. J Biol Chem. 2012. PMID: 22081603 Free PMC article.

7

Fibroblast growth factor inducible (Fn14)-specific antibodies concomitantly display signaling pathway-specific agonistic and antagonistic activity.

Salzmann S, Seher A, Trebing J, Weisenberger D, Rosenthal A, Siegmund D, Wajant H. Salzmann S, et al. Among authors: wajant h. J Biol Chem. 2013 May 10;288(19):13455-66. doi: 10.1074/jbc.M112.435917. Epub 2013 Mar 26. J Biol Chem. 2013. PMID: 23532848 Free PMC article.

8

TWEAK inhibits TRAF2-mediated CD40 signaling by destabilization of CD40 signaling complexes.

Salzmann S, Lang I, Rosenthal A, Schäfer V, Weisenberger D, Carmona Arana JA, Trebing J, Siegmund D, Neumann M, Wajant H. Salzmann S, et al. Among authors: wajant h. J Immunol. 2013 Sep 1;191(5):2308-18. doi: 10.4049/jimmunol.1202899. Epub 2013 Aug 5. J Immunol. 2013. PMID: 23918987

9

Exogenous administration of a recombinant variant of TWEAK impairs healing after myocardial infarction by aggravation of inflammation.

Pachel C, Mathes D, Bayer B, Dienesch C, Wangorsch G, Heitzmann W, Lang I, Ardehali H, Ertl G, Dandekar T, Wajant H, Frantz S. Pachel C, et al. Among authors: wajant h. PLoS One. 2013 Nov 11;8(11):e78938. doi: 10.1371/journal.pone.0078938. eCollection 2013. PLoS One. 2013. PMID: 24244389 Free PMC article.

10

TNF Receptor-Associated Factor 1 is a Major Target of Soluble TWEAK.

Carmona Arana JA, Seher A, Neumann M, Lang I, Siegmund D, Wajant H. Carmona Arana JA, et al. Among authors: wajant h. Front Immunol. 2014 Feb 18;5:63. doi: 10.3389/fimmu.2014.00063. eCollection 2014. Front Immunol. 2014. PMID: 24600451 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

213 results

Search Page